Paragon Capital Management LLC continued to hold its position in shares of Mylan (NASDAQ:MYL) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,821 shares of the company’s stock at the end of the first quarter. Paragon Capital Management LLC’s holdings in Mylan were worth $265,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. First Personal Financial Services boosted its stake in Mylan by 33.2% in the first quarter. First Personal Financial Services now owns 2,733 shares of the company’s stock valued at $107,000 after buying an additional 681 shares during the last quarter. Kernodle & Katon Asset Management Group LLC boosted its stake in Mylan by 4.7% in the third quarter. Kernodle & Katon Asset Management Group LLC now owns 2,884 shares of the company’s stock valued at $110,000 after buying an additional 129 shares during the last quarter. Ropes Wealth Advisors LLC bought a new stake in Mylan during the first quarter valued at $136,000. Mosaic Family Wealth LLC boosted its stake in Mylan by 12.5% in the third quarter. Mosaic Family Wealth LLC now owns 3,600 shares of the company’s stock valued at $137,000 after buying an additional 400 shares during the last quarter. Finally, Oakworth Capital Inc. boosted its stake in Mylan by 30.7% in the first quarter. Oakworth Capital Inc. now owns 4,255 shares of the company’s stock valued at $166,000 after buying an additional 1,000 shares during the last quarter. 60.89% of the stock is owned by hedge funds and other institutional investors.
Shares of Mylan (NASDAQ:MYL) traded down 0.55% on Friday, reaching $37.94. 3,434,765 shares of the company’s stock were exchanged. Mylan has a 52-week low of $33.60 and a 52-week high of $50.40. The stock has a market cap of $20.33 billion, a P/E ratio of 37.90 and a beta of 1.14. The company’s 50 day moving average price is $38.13 and its 200-day moving average price is $38.73.
Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Wednesday, May 10th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.92 by $0.01. The company had revenue of $2.72 billion during the quarter, compared to the consensus estimate of $2.81 billion. Mylan had a net margin of 2.50% and a return on equity of 22.04%. The company’s quarterly revenue was up 24.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.76 EPS. Equities analysts forecast that Mylan will post $5.17 EPS for the current fiscal year.
MYL has been the subject of several research reports. Vetr cut shares of Mylan from a “strong-buy” rating to a “buy” rating and set a $44.68 price objective for the company. in a research report on Monday, February 6th. Zacks Investment Research upgraded shares of Mylan from a “sell” rating to a “hold” rating in a research report on Monday, February 27th. Mizuho restated a “buy” rating and issued a $47.00 price objective on shares of Mylan in a research report on Tuesday, February 28th. Royal Bank of Canada set a $48.00 price objective on shares of Mylan and gave the company a “hold” rating in a research report on Thursday, March 2nd. Finally, Guggenheim restated a “neutral” rating on shares of Mylan in a research report on Friday, March 3rd. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. Mylan presently has an average rating of “Buy” and an average target price of $51.58.
In other news, major shareholder Laboratories Abbott sold 44,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $41.60, for a total transaction of $1,830,400,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.71% of the company’s stock.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.